Memo Therapeutics
PrivateLast Round
Series C
Extension
May 7, 2024
Total Funding Raised
$108.66M
Momentum Score
25 /100
Company Overview
Memo Therapeutics is a biotechnology company that offers an innovative platform for antibody discovery and immune repertoire analysis aimed at improving the lives of patients with viral infections and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Memo Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Memo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | May 7, 2024 | ||||
| Series C | Nov 2, 2023 | ||||
| Series B Extension | Feb 16, 2022 | ||||
| Grant | Dec 14, 2021 | ||||
| Series B | Nov 6, 2020 | ||||
Series A Extension | May 9, 2018 |
Key People
Founding team and executive leadership
Memo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Verve Ventures | Series B, Series B Extension, Series C Extension, Series C, Series A Extension |
| Jaquet Partners | Series B |
| Vesalius Biocapital III | Series B Extension |
| Ysios Capital | Series C Extension |
| Vesalius Biocapital Partners | Series C |
| Fresenius Medical Care Ventures | Series B Extension, Series C Extension, Series C |
| BERNINA BioInvest AG | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 9, 2026
Partnered with CSL for Recombinant Polyclonal IgG technology development.
- Nov 7, 2025
Presented Phase II trial data at ASN Kidney Week Meeting.
Memo Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Memo Therapeutics's valuation, stock price, and market status.
